Daiichi Sankyo Co Ltd (4568) - Financial and Strategic SWOT Analysis Review

Daiichi Sankyo Co Ltd (4568) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Daiichi Sankyo Co Ltd (Daiichi Sankyo) is a holding company which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrologic, diabetic, metabolic and infectious diseases; and various types of cancers. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

Daiichi Sankyo Co Ltd Key Recent Developments

May 11,2020: Daiichi Sankyo announces changes to representative directors and members of the board
Apr 14,2020: Daiichi Sankyo contributes to relief efforts for countermeasures against COVID-19
Feb 21,2020: Daiichi Sankyo appoints new corporate officers
Jan 31,2020: Daiichi Sankyo Company: Announcement of the third quarter FY2019 financial results
Nov 04,2019: Daiichi Sankyo files declaratory judgement action related to its proprietary antibody drug conjugate Technology

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 

 
Section 1 - About the Company
Daiichi Sankyo Co Ltd - Key Facts
Daiichi Sankyo Co Ltd - Key Employees
Daiichi Sankyo Co Ltd - Key Employee Biographies
Daiichi Sankyo Co Ltd - Major Products and Services
Daiichi Sankyo Co Ltd - History
Daiichi Sankyo Co Ltd - Company Statement
Daiichi Sankyo Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Daiichi Sankyo Co Ltd - Business Description
Business Segment: Healthcare (OTC) Products
Overview
Performance
Business Segment: Others
Performance
Business Segment: Prescription Drugs
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other Regions
Performance
R&D Overview
Daiichi Sankyo Co Ltd - Corporate Strategy
Daiichi Sankyo Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Daiichi Sankyo Co Ltd - Strengths
Daiichi Sankyo Co Ltd - Weaknesses
Daiichi Sankyo Co Ltd - Opportunities
Daiichi Sankyo Co Ltd - Threats
Daiichi Sankyo Co Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Daiichi Sankyo Co Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 11, 2020: Daiichi Sankyo announces changes to representative directors and members of the board
Apr 14, 2020: Daiichi Sankyo contributes to relief efforts for countermeasures against COVID-19
Feb 21, 2020: Daiichi Sankyo appoints new corporate officers
Jan 31, 2020: Daiichi Sankyo Company: Announcement of the third quarter FY2019 financial results
Nov 04, 2019: Daiichi Sankyo files declaratory judgement action related to its proprietary antibody drug conjugate Technology
Oct 16, 2019: Daiichi Sankyo buys multiple drugs from Astellas Pharma
Aug 06, 2019: Daiichi Sankyo Company: Consolidated financial results for the first three months of the year ending march 31, 2020 (fiscal 2019)
May 28, 2019: Integral Molecular reaches milestone in immuno-oncology target discovery collaboration with Daiichi Sankyo
May 17, 2019: Daiichi Sankyo announces update to H5N1 influenza vaccine national project
May 10, 2019: Daiichi Sankyo announces changes to members of the Board and members of the Audit and Supervisory Board
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables


Daiichi Sankyo Co Ltd, Key Facts
Daiichi Sankyo Co Ltd, Key Employees
Daiichi Sankyo Co Ltd, Key Employee Biographies
Daiichi Sankyo Co Ltd, Major Products and Services
Daiichi Sankyo Co Ltd, History
Daiichi Sankyo Co Ltd, Subsidiaries
Daiichi Sankyo Co Ltd, Joint Venture
Daiichi Sankyo Co Ltd, Key Competitors
Daiichi Sankyo Co Ltd, Ratios based on current share price
Daiichi Sankyo Co Ltd, Annual Ratios
Daiichi Sankyo Co Ltd, Annual Ratios (Cont...1)
Daiichi Sankyo Co Ltd, Annual Ratios (Cont...2)
Daiichi Sankyo Co Ltd, Interim Ratios
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Daiichi Sankyo Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
 


List Of Figures


Daiichi Sankyo Co Ltd, Performance Chart (2016 - 2020)
Daiichi Sankyo Co Ltd, Ratio Charts
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
 


Musculoskeletal Disorders Drugs Global Market Forecast To 2022 Including: Drugs For Rheumatoid Arthritis, Muscle Relaxants, Others - Musculoskeletal Disorders Drugs Covering: F. Hoffmann-La Roche Ltd, GlaxosmithKline Plc, Pfizer Inc, Abbott Laboratories Inc, Daiichi Sankyo Company

The musculoskeletal disorders drugs market consists of sales of musculoskeletal disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce musculoskeletal disorders drugs to treat musculoskeletal

USD 4000 View Report

Hematology Drugs Global Market Forecast To 2022 Including: Blood Products, Anemia And Other Blood Disorder Drugs Covering: Novo Nordisk A/S, Shire Plc, Bayer AG, Daiichi Sankyo Company, Biogen Inc

The hematology drugs market consists of sales of hematology drugs and related services by entities (organizations, sole traders and partnerships) that produce hematology drugs to treat diseases such as genetic

USD 4000 View Report

Musculoskeletal Disorders Drugs Global Market Forecast To 2022 Including: Drugs For Rheumatoid Arthritis, Muscle Relaxants, Others - Musculoskeletal Disorders Drugs Covering: F. Hoffmann-La Roche Ltd, GlaxosmithKline Plc, Pfizer Inc, Abbott Laboratories Inc, Daiichi Sankyo Company

The musculoskeletal disorders drugs market consists of sales of musculoskeletal disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce musculoskeletal disorders drugs to treat musculoskeletal

USD 4000 View Report

Hematology Drugs Global Market Forecast To 2022 Including: Blood Products, Anemia And Other Blood Disorder Drugs Covering: Novo Nordisk A/S, Shire Plc, Bayer AG, Daiichi Sankyo Company, Biogen Inc

The hematology drugs market consists of sales of hematology drugs and related services by entities (organizations, sole traders and partnerships) that produce hematology drugs to treat diseases such as genetic

USD 4000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available